

HCV epidemiology in high-risk groups and the risk of reinfection

Håvard Midgard^{1,2,3,*}, Amanda Weir^{4,5}, Norah Palmateer^{4,5}, Vincent Lo Re III⁶, Juan A. Pineda⁷, Juan Macías⁷, Olav Dalgard^{1,2}

Summary

Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual practices among men who have sex with men (MSM) are important routes of hepatitis C virus (HCV) transmission. Current direct-acting antiviral treatment offers unique opportunities for reductions in HCV-related liver disease burden and epidemic control in high-risk groups, but these prospects could be counteracted by HCV reinfection due to on-going risk behaviours after successful treatment. Based on existing data from small and heterogeneous studies of interferon-based treatment, the incidence of reinfection after sustained virological response range from 2–6/100 person years among PWID to 10–15/100 person years among human immunodeficiency virus-infected MSM. These differences mainly reflect heterogeneity in study populations with regards to risk behaviours, but also reflect variations in study designs and applied virological methods. Increasing levels of reinfection are to be expected as we enter the interferon-free treatment era. Individual- and population-level efforts to address and prevent reinfection should therefore be undertaken when providing HCV care for people with on-going risk behaviour. Constructive strategies include acknowledgement, education and counselling, harm reduction optimization, scaled-up treatment including treatment of injecting networks, post-treatment screening, and rapid retreatment of reinfections.

© 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Keywords: HCV; Reinfection; Epidemiology; PWID; MSM; Injecting drug use; Risk behaviours.

Received 24 May 2016; received in revised form 8 July 2016; accepted 12 July 2016

Abbreviations: PWID, people who inject drugs; MSM, men who have sex with men; HCV, hepatitis C virus; IDU, injecting drug use; DAA, direct-acting antiviral; PY, person-years; NSP, needle/syringe provision; OST, opioid substitution treatment; HIV, human immunodeficiency virus; SVR, sustained virological response; RNA, ribonucleic acid; NGS, next generation sequencing; PCR, polymerase chain reaction.

Introduction

In high-income countries, injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual practices among men who have sex with men (MSM) are important routes of hepatitis C virus (HCV) transmission [1–3]. The majority of HCV patients in these populations have been chronically infected for many years and no longer take part in risk behaviour. Still, approximately one in four individuals with chronic HCV acquired through injecting drug use (IDU) have recently injected drugs [4] and thereby continue to be at risk of new HCV exposure.

People with on-going risk behaviour have been successfully treated for HCV infection [5–7]. However, treatment uptake was low during the interferon (IFN) era, particularly among PWID [8,9]. With the current availability of tolerable and highly effective IFN-free direct-acting antiviral (DAA) drugs, increased treatment rates and subsequent rising reinfection rates might be anticipated in high-risk groups.

The potential impact of reinfection is of considerable clinical and public health interest [10–12]. High levels of reinfection could compromise individual treatment benefits but also impede population efforts to limit the HCV epidemic. This review provides updated information on the epidemiology of HCV infection and the risk of reinfection after successful treatment in high-risk groups of PWID and MSM. Particular emphasis is given to the section on reinfection, in which methodological considerations, incidence rates, risk factors, and preventive strategies are discussed.

HCV epidemiology in high-risk groups

HCV epidemiology among PWID

Prevalence of injecting

Globally, there are an estimated 14 million PWID (range 11.2–22.0 million) who are at-risk of HCV

¹Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway;

²Institute for Clinical Medicine, University of Oslo, Norway;

³Department of Gastroenterology, Oslo University Hospital, Norway;

⁴School of Health and Life Sciences, Glasgow Caledonian University, United Kingdom;

⁵NHS National Services Scotland, Health Protection Scotland, Glasgow, United Kingdom;

⁶Division of Infectious Diseases, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, United States;

⁷Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, Spain

infection as a result of injecting practices that may expose them to contaminated blood [13]. In most developed countries, IDU increased in the 1970s and 1980s and is now the main risk factor for HCV infection in these countries [14–16]. A recent review estimated the total number of current PWID across Europe to be 4.5 million [17].

Prevalence of HCV infection

Anti-HCV prevalence among PWID has been estimated at 67% worldwide, corresponding to 10 million anti-HCV positive PWID (range 6–15.2 million). While the prevalence varies greatly between countries, the majority report prevalence estimates above 60% [1]. This is the case in Europe, where the recorded midpoint prevalence estimates range from 21.1% to 90.5% with approximately half of all countries estimated to have 60% prevalence and above [1]. By region, the largest anti-HCV positive PWID populations are estimated to live in Eastern Europe (2.3 million) and East and South-East Asia (2.6 million); by country, the largest PWID populations are estimated to live in China (1.6 million), Russian Federation (1.3 million), and the USA (1.5 million) [1]. The total number of anti-HCV positive PWID in Europe is estimated to be 2.7 million, with 2.0 million being chronically infected (Fig. 1) [17]. A European systematic review estimates the viremic prevalence in PWID to be between 53% and 97% [18].

Incidence of HCV infection

In contrast to prevalence, no pooled global estimate of incidence among non-incarcerated PWID has been reported; however, a number of studies have reported incidence rates among selected local PWID populations. A systematic review (comprising data from nine European countries) identified 11 studies that reported a median incidence of 26/100 person-years (PY) among current PWID in the community [18]. A review and meta-analysis of HCV in prisons found a summary incidence rate of 16.4/100 PY among prisoners with a history of injecting [19].

Risk factors for HCV acquisition

Sharing needle/syringes is acknowledged to be the main route of HCV acquisition among PWID since direct percutaneous exposure to contaminated blood from a needle/syringe has been demonstrated to transmit HCV [20–22]. The risk of transmission associated with a given sharing event would, however, depend on a number of factors, such as the quantity of blood inoculated and the viral load. Ancillary injecting equipment (spoons/cookers, filters, and water) may also become contaminated with HCV during the process of preparing and injecting drugs. Sharing cookers and filters has been associated with an increased risk of HCV in epidemiological studies: while the probability of HCV transmission associated with

the latter is likely less than that for sharing needles/syringes, the generally higher prevalence of sharing cookers/filters may increase their contribution to the proportion of new HCV infections [23–25]. While there is evidence of a decline in the rates of needle/syringe sharing in some countries, this risk behaviour nevertheless persists among PWID [26–28]. A similar decline has been seen in Western European countries [29–32]; however, the prevalence of sharing needles/syringes may remain high in Eastern Europe [33]. Furthermore, the sharing of ancillary injecting equipment appears to remain more prevalent than needle/syringe sharing [29,34].

Harm reduction

Harm reduction is defined as the policies, programmes, and practices that aim to reduce the harms associated with the use of psychoactive drugs among people who are unable or unwilling to stop [35]. The main harm reduction interventions are generally considered to be sterile needle/syringe provision (NSP) and opioid substitution treatment (OST). There is evidence to support the effectiveness of NSP and OST in reducing injecting risk behaviour, and some evidence to support their effectiveness in preventing blood-borne virus transmission among PWID [36,37].

More recently, studies have demonstrated that the combined impact of NSP and OST can produce a greater reduction in HCV transmission than either intervention alone [32,38–40]. These interventions have been endorsed by national, regional, and international authorities for the prevention of HCV [41–44]. However, despite the availability of, and evidence for, effective harm reduction, most countries have not achieved a level of intervention coverage that would likely be required to curb new HCV infections: on a global level, there is generally poor coverage of interventions, with NSP coverage estimated at 22 sterile needles/syringes per PWID per year and OST coverage estimated at 8 OST recipients per 100 PWID. The highest NSP coverage is in Australia & New Zealand (202 needles/syringes per PWID per year) and the highest OST coverage is in Western Europe (61 OST recipients per 100 PWID) [45].

The experience of some countries that have achieved high levels of harm reduction intervention coverage is, however, that they can reduce, but not fully control, HCV transmission among PWID [32,46]. This may be because high coverage needs to be sustained for decades in order to have an impact. For example, model projections have shown that, in a scenario of 40% viremic prevalence, reducing HCV prevalence by a third would require more than 60% coverage of both OST and high coverage NSP for 15 years [47]. More impact could probably be achieved through a treatment-as-prevention strategy: modelling studies have suggested that scaling up HCV therapy among active PWID (in addition to the existing harm reduction interventions) is necessary if substantial reductions in HCV

Key point

Combined harm reduction interventions (needle/syringe provision and opioid substitution treatment) could reduce HCV transmission among PWID, but effective interventions to prevent HCV transmission among MSM have not been developed.

Key point

Sharing needle/syringes and contaminated ancillary injecting equipment (spoons/cookers, filters, and water) are the main risk factors for HCV acquisition among PWID.

* Corresponding author. Address: Akershus University Hospital, 1478 Lørenskog, Norway. Tel.: +47 90 83 00 71. E-mail address: havardmi@medisin.uio.no (H. Midgard).




Fig. 1. Prevalence of antibodies to hepatitis C virus (anti-HCV) in the WHO European region, by country. (A) Across the general population. (B) Across the population of people who inject drugs (PWID). Dotted areas indicate countries outside the WHO European region. Adapted from Hope *et al.* 2014 [17].

prevalence over the next decade or two are to be made [48,49].

HCV epidemiology among MSM

Prevalence of HCV infection

Cross-sectional studies have revealed an anti-HCV prevalence of 1–7% among MSM without a history of IDU compared to 25–50% among MSM with a history of IDU [50–55]. Further, HCV infection is more frequent among MSM with human immunodeficiency virus (HIV) infection (3–39%) than in those without HIV (0–19%) [51–53,56–59]. The HCV prevalence among HIV-negative MSM without IDU is comparable to that of the general population [60–63].

Incidence of HCV infection

Beginning in 2004, an increase in the incidence of acute HCV infection was reported among HIV-infected MSM in Europe, North America, Australia, and Asia [60,63–80,11,14–31]. A systematic review of these studies found that the incidence of acute HCV from 2000–2012 was approximately four times higher in HIV-positive MSM (0.61/100 PY) than HIV-negative MSM (0.15/100 PY) [81]. Data from 3014 HIV-infected MSM from 12 cohorts within the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) collaboration showed that the HCV incidence increased from 0.55–0.81/100 PY in 1995 to 2.34–5.11/100 PY in 2007 [76]. Similar rises were observed among HIV-infected MSM in North America, Australia, and Asia [63,75,77,79,80]. One phylogenetic analysis revealed a large European-wide network of HCV transmission among HIV-infected MSM coinciding with the introduction of combination antiretroviral therapy and associated increases in sexual risk behaviours [82].

Risk factors for HCV acquisition

Per mucosal (particularly sexual) transmission is the predominant route of HCV acquisition among MSM, especially in HIV-infected individuals

[53,83]. Use of mucosally administered recreational drugs (e.g., methamphetamines, ketamine, gammahydroxybutyrate, lysergic acid diethylamide) [62,84–87] and high-risk traumatic sex practices, particularly unprotected anal intercourse, enema use prior to receptive anal intercourse, rectal trauma with bleeding, fisting, and group sex [58,68,72,84,85,87,88], have been identified as important behavioural risk factors for HCV transmission among MSM. The arrival of “chemsex” (i.e., injecting and non-injecting drug use to enhance sexual experience) might further promote HCV transmission among MSM [89]. Additionally, HIV and ulcerative sexually transmitted infections are important biological risk factors for per mucosally acquired HCV [68,84,85,87]. HIV infection increases HCV RNA levels [90] and promotes shedding of HCV in serum [91–93]. Ulcerative sexually transmitted infections disrupt the mucosal integrity of the genitourinary tract, facilitating HCV per mucosal transmission [78,84,85,87,88,94,95].

Prevention

A recent study evaluating a dynamic HCV transmission model among HIV-infected MSM in the UK Collaborative HIV Cohort suggested that substantial reductions in HCV transmission could be achieved through scale-up of DAA drugs for the treatment of chronic HCV and effective behavioural interventions [96]. However, effective behavioural interventions to prevent HCV transmission have not been developed and tested in MSM. Targeted prevention messages that combine sexual health advice and avoidance of recreational drug use and which encourage MSM to discuss HCV with their partners might be helpful in preventing HCV infection [97–99]. Repeated risk counselling on HCV transmission before, during, and after HCV treatment might also be beneficial for HCV prevention [7]. A recent randomized trial has shown that a reduction in high-risk sexual practices after a social network intervention led to a decline in the incidence of sexually transmitted diseases/HIV from 15% to 9% [100].

Key point

Risk factors for HCV acquisition among MSM include traumatic sexual practices, mucosally administered and injecting recreational drug use, HIV infection, and ulcerative sexually transmitted infections.

Key point

Scaled-up DAA treatment and effective harm reduction/preventive interventions are required to substantially reduce HCV prevalence among PWID and MSM, but high levels of reinfection due to on-going risk behaviour could compromise both individual- and population-level treatment benefits.

HCV reinfection in high-risk groups

General considerations

The lack of protective immunity

HCV reinfection after spontaneous clearance of the virus has been observed in chimpanzees [101,102] and in humans [7,103–114]. As reviewed elsewhere [115], some of these studies have demonstrated evidence of an augmented HCV-specific immune response following reinfection compared to after primary infection, suggesting that some immunological control may develop after repeated exposure to the virus. As this only seems to apply when exposed to a homologous HCV strain, one can at best hope for an acquired partial, but no protective, immunity against reinfection in clinical practice. The lack of protective immunity has also been evident in efforts to develop HCV vaccines, which so far have been complicated by the great genetic diversity of HCV, complex immunological responses to the virus, and the limited availability of animal models and at-risk cohorts [116,117].

Heterogeneity and limitations of reinfection studies

Reinfection following sustained virological response (SVR) has over the last 10–15 years been documented in several studies in populations of PWID [118–127], prisoners [128,129], and MSM [7,98,114,130–132] (Tables 1 and 2). The reinfection incidence estimates reported in these studies have ranged considerably, reflecting differences in study populations with regards to risk behaviours, harm reduction coverage, and background viremic prevalence. Furthermore, most studies have been limited either by small sample sizes, short longitudinal follow-up, retrospective study designs, or insufficient risk factor assessment. Finally, differences in virological methods may also have biased the reported reinfection estimates and accounted for some of the variation observed between studies. Collectively, all these aspects have made generalizability and comparisons between studies challenging.

Testing intervals – “the more often you look”

Some of the inter-study variability in reinfection estimates could be explained by differences in HCV testing intervals [133]. Observational data have demonstrated that reinfections often have a transient course with high rates of spontaneous clearance [112,113,134]. Thus, the event has probably generally been underestimated, as reinfection episodes with spontaneous clearance most likely will remain undetected unless HCV RNA is tested very frequently. Studies with wide testing intervals will therefore mainly capture those reinfections that have become persistent.

Sequencing methods – “the closer you look”

Recurrence of HCV RNA after SVR could result from one of three possible scenarios: late relapse of the pre-treatment majority variant, persistence/

re-emergence of a pre-existing treatment-insensitive minority variant (either detected or undetected), or reinfection with a new viral strain not present at baseline [135,136] (Fig. 2). This is an important distinction of both clinical and academic relevance, but correct classification is challenging and requires sensitive sequencing methods and robust phylogenetic analysis [137]. So far, there has been no standardisation of such methods, and studies employing insensitive techniques [7,119–121, 124,127–129,138] may thus have had a potential to misclassify cases of late relapse as reinfection. On the other hand, among individuals with apparent relapse, it is very difficult to exclude the possibility of reinfection from the same source as the initial infection.

The relapse/reinfection distinction rests upon the detection of potential minority variants present in pre-treatment samples. This is relevant for individuals with on-going risk behaviour, who might harbour mixed infections resulting from either co-infections or superinfections due to repeated exposure to HCV [136]. Conventional line probe assays are widely used but have poor sensitivity for detection of minority variants that constitute <20% of the total virus population [139–143]. When using more sensitive methods [111,144,145], the reported prevalence of mixed infection in populations of PWID increases from <5% to 20–40%. In a study of MSM with HIV co-infection who had failed to respond to IFN-based HCV treatment, 15 of 15 participants had evidence of mixed infection when next generation sequencing (NGS) was performed [146]. Although the presence of mixed infection at baseline may compromise IFN-based HCV treatment outcomes [123,147], its clinical significance remains controversial.

Most reinfection studies utilizing sequencing methods have applied majority population-based sequencing (i.e., Sanger sequencing) [98,114,122,123,125,126], but NGS is emerging as the state-of-the-art method [146,148]. Compared to population-based sequencing, NGS offers high throughput analysis with superior sensitivity, but at the same time generates large amounts of data that require costly bioinformatics and phylogenetic analysis. However, unless the whole genome is analysed, the choice of region to be sequenced and the exact design of PCR primers may influence the analysis and ultimately lead to misclassification bias [135,136].

A pragmatic approach

In studies of low-risk populations, the reported risk of late relapse (i.e., post-SVR recurrence of HCV RNA) is very low, with 5- and 10-year cumulative estimates of <1% [149]. In the presence of on-going risk behaviour, post-SVR recurrence of HCV RNA therefore most likely represents reinfection. In the absence of a virological gold standard to confirm a “true” reinfection diagnosis, we would therefore

Key point

Differences in reported reinfection estimates reflect heterogeneity in study populations with regards to risk behaviour, and variations in study design and applied virological methods.

Table 1. Characteristics of studies of hepatitis C virus reinfection after sustained virological response among people who inject drugs and men who have sex with men.

Study	Location	Design	SVR	Population	HCV infection	HIV	OST	Risk behaviour baseline	Risk behaviour post-SVR
Dalgard <i>et al.</i> 2002 [118]	Norway	Retrospective follow-up	27	PWID	Chronic	0%	0%	0%	33%
Backmund <i>et al.</i> 2004 [119]	Germany	Prospective cohort	18	PWID	Chronic	n.r.	39%	n.r.	50%
Currie <i>et al.</i> 2008 [120]	United States	Prospective cohort	9	PWID	Chronic	56%	n.r.	0%	22%
Grebely <i>et al.</i> 2010 [121]	Canada	Prospective cohort	35	PWID	Chronic	6%	43%	54%	46%
Grady <i>et al.</i> 2012 [122]	Netherlands	Prospective cohort	42	PWID	Chronic	2%	93%	100%	26%
Grebely <i>et al.</i> 2012 [123]	Australia	Prospective cohort	67	PWID	Acute	33%	n.r.	35%	38%
Hilsden <i>et al.</i> 2013 [124]	Canada	Prospective/RCT	23	PWID	Chronic	0%	27%	85%	n.r.
Pineda <i>et al.</i> 2015 [125]	Spain	Retrospective cohort	84	PWID	Chronic	100%	24%	n.r.	15%
Midgard <i>et al.</i> 2016 [126]	Norway	Retrospective follow-up	94	PWID	Chronic	0%	0%	0%	39%
Weir <i>et al.</i> 2016 [127]	Scotland	Retrospective registry study	277	PWID	Chronic	n.r.	n.r.	n.r.	11%
Bate <i>et al.</i> 2010 [128]	Australia	Retrospective review	53	Prisoners	Chronic	0%	n.r.	n.r.	n.r.
Marco <i>et al.</i> 2013 [129]	Spain	Prospective-retrospective	119	Prisoners	Chronic	15%	100%	20%	n.r.
Lambers <i>et al.</i> 2011 [98]	Netherlands	Retrospective/prospective	51	MSM	Acute	100%	n.a.	n.r.	n.r.
Martin <i>et al.</i> 2013 [7]	United Kingdom	Retrospective	114	MSM	Acute/unknown	100%	n.a.	n.r.	n.r.
Vanhommerig <i>et al.</i> 2014 [130]	Netherlands	Retrospective	31	MSM	Acute	100%	n.a.	n.r.	n.r.

PWID, people who inject drugs; MSM, men who have sex with men; SVR, sustained virological response; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OST, opioid substitution treatment; n.r., not reported; n.a., not applicable.

advise a pragmatic approach, taking post-treatment risk factors thoroughly into account.

Incidence of HCV reinfection after SVR among PWID

Reinfection after interferon-based treatment

Two pioneering studies among former and current PWID [118,119] confirmed that HCV reinfection after SVR was indeed possible, albeit occurring at low rates. Most succeeding reports stated similarly low rates, and a meta-analysis [5] of the five first studies published from 2002 to 2012 [118–122] reported a pooled incidence of 2.4/100 PY. Among individuals with documented on-going risk behaviour after SVR, the pooled incidence was moderately higher (6.1/100 PY). However, the results from this meta-analysis should be interpreted with caution, as it was based on small studies of heterogeneous populations that included patients with relatively short follow-up time. Also, these early studies largely lacked sequencing methods to strengthen the reinfection diagnosis.

An Australian study among people with acute HCV infection [123], in which 76% had a history of IDU and 35% reported recent IDU at enrolment, pioneered sensitive sequencing methods using subtype-specific real-time PCRs for detecting mixed HCV infection. This study provided a detailed characterization of the natural history of reinfection and superinfection (i.e., the detection of a HCV strain distinct from the primary strain in those with virological persistence) among treated

and untreated individuals. Among 67 individuals who achieved SVR, 12 cases of relapse and 5 cases of reinfection were detected. This generated a higher post-SVR reinfection rate (12.3/100 PY) than reported in previous studies, possibly reflecting the inclusion of participants with recently acquired HCV infection and still on-going high-risk behaviours. This study was also the first to identify independent risk factors for reinfection. Reinfection or superinfection occurred significantly more often in participants with poorer baseline social functioning and in those who reported methamphetamine injecting compared to opiate injecting during follow-up. Interestingly, reinfection was not associated with baseline injecting status, indicating that prediction of reinfection may prove difficult in this population.

HCV infection is common in prison populations worldwide [19]. Although the prison setting may be considered as an opportunity for HCV treatment, it may also be an important site for HCV transmission and hence reinfections. The incidence of reinfection after HCV treatment provided in prison was investigated in an incarcerated cohort in Spain [129], of which 15% were HIV/HCV co-infected. Among 119 prisoners who obtained SVR, 9 (7.6%) were reinfected after a mean follow-up of 1.4 years, generating an overall incidence of 5.3/100 PY. Self-reported data on risk behaviour were unreliable, as four reinfected individuals reported no risk factors; thus, no reasonable reinfection estimate could be given among those who continued to inject drugs

Table 2. Incidence estimates of hepatitis C virus reinfection after sustained virological response and applied methods in studies among people who inject drugs and men who have sex with men.

Study	Population	SVR	FU, mean yr	PYFU/PYFU post-SVR risk	Method	Testing interval, yr	Reinfections	Incidence (overall/post-SVR risk), per 100 PY
Dalgard <i>et al.</i> 2002 [118]	PWID	27	5.4	118/40	Genotyping Risk factors	1-7	1	0.8/2.5
Backmund <i>et al.</i> 2004 [119]	PWID	18	2.8	51/24	Genotyping Risk factors	1	2	3.9/8.4
Currie <i>et al.</i> 2008 [120]	PWID	9	3.6	38/3.5	HCV RNA Risk factors	0.5	1	0.56/1.89
Grebely <i>et al.</i> 2010 [121]	PWID	35	2.0	63/38	Genotyping Risk factors	1	2	3.2/5.3
Grady <i>et al.</i> 2012 [122]	PWID	42	2.5	132/32	Sequencing	0.5-1	1	0.8/3.4
Grebely <i>et al.</i> 2012 [123]	PWID	67	1.1	140/56	Sequencing Risk factors	0-2	5	12.3/7.3
Hilsden <i>et al.</i> 2013 [124]	PWID	23	1.8	36/n.r.	HCV RNA	n.r.	1	2.8/n.r.
Pineda <i>et al.</i> 2015 [125]	PWID	84	2.8	330/n.r.	Sequencing Risk factors	0.5	4	1.2/8.7
Midgard <i>et al.</i> 2016 [126]	PWID	94	7.1	593/206	Sequencing Risk factors	0.5-8	10*	1.7/4.9
Weir <i>et al.</i> 2016 [127]	PWID	277	4.5	410/n.r.	Genotyping Risk factors	n.r.	7	1.7/5.7
Bate <i>et al.</i> 2010 [128]	Prisoners	53	3.4	n.r.	Genotyping	n.r.	5	n.r.
Marco <i>et al.</i> 2013 [129]	Prisoners	119	1.4	171/n.r.	Genotyping Risk factors	1	9	5.3/n.r.
Lambers <i>et al.</i> 2011 [98]	MSM	55	1.3	72/n.r.	Sequencing Risk factors	0.25	11	15.2/n.r.
Martin <i>et al.</i> 2013 [7]	MSM	114	1.6	224/n.r.	HCV RNA	n.r.	27	9.6/n.r.
Vanhommerig <i>et al.</i> 2014 [130]	MSM	31	4.0	n.r.	Sequencing	0.5	8	n.r.

*Persistent reinfections.

PWID, people who inject drugs; MSM, men who have sex with men; SVR, sustained virological response; FU, follow-up; PYFU, person-years of follow-up; PY, person-years; n.r., not reported.

after treatment. However, reinfection was three times more common in HIV-positive than in HIV-negative subjects (13.4 vs. 4.0/100 PY).

Conversely, in another Spanish study of 84 HIV/HCV co-infected individuals [125], a much lower incidence of reinfection (1.2/100 PY) was found. This was an overall low-risk population mainly comprising former PWID or individuals on stable OST, but in the subgroup reporting risk behaviours during follow-up, 3 of 11 were reinfected (incidence 8.7/100PY).

A newly published comprehensive meta-analysis [150] included 14 articles or conference abstracts among PWID or prisoners and 4 studies of HIV/HCV co-infected individuals from heterogeneous populations. Among a total of 771 PWID or prisoners, 42 cases of HCV RNA recurrence after SVR were observed. The pooled reinfection incidence was 1.9/100 PY, leading to an estimated 5-year risk of 10%. Among HIV/HCV co-infected individuals, the pooled incidence of reinfection was higher (3.2/100 PY), leading to an estimated 5-year risk of 15%. However, given that these estimates largely were based on data from small studies, there is still considerable uncertainty regarding generalizability and the actual long-term risk of reinfection.

In a recent Norwegian study [126], long-term reinfection rates were assessed in 94 individuals with a history of IDU who had achieved SVR in a

treatment trial performed in 2002–2004. Notably, the study population was not a typical high-risk group, as six months of abstinence from IDU was required before treatment. Nevertheless, 39% had relapsed to IDU at some point after treatment. After a median of seven years after SVR, persistent reinfection was observed in 11% of individuals with a history of IDU prior to treatment (incidence 1.7/100 PY) and in 27% of individuals who reported IDU after treatment (incidence 4.9/100 PY). Although all episodes occurred among individuals with IDU after treatment, reinfection was not associated with any baseline variable; however, relapse to IDU was associated with younger age and low education level. While these estimates are in line with previous reports, direct comparison may be difficult due to the study's retrospective design with wide testing intervals and subsequent underestimation of all reinfection episodes. The study also highlights the vulnerability of viral sequencing of old serum samples with degradation of HCV RNA and low viral loads, which led to adequate sequences being obtained only in a minority of samples.

The long-term risk of reinfection has also been evaluated retrospectively in a large Scottish cohort of former and current PWID who had obtained SVR between 2000 and 2009 [127]. Risk behaviour post-SVR was assessed by registry linkage, and hospitalisation for an opiate- or injection-related cause during follow-up was considered a proxy for




Fig. 2. Recurrence of HCV RNA after sustained virological response. This could result from either (A) late relapse of a majority variant, (B) persistence/re-emergence of a pre-existing minority variant, or (C) reinfection with a new viral strain. TW0, treatment week 0; EOT, end of treatment; SVR, sustained virological response; LOD, level of detection.

continued IDU. Among 277 individuals who were tested for HCV RNA after SVR, 7 reinfections were observed after a median of 4.5 years. Consistent with results from previous studies, the reinfection incidence was 1.7/100 PY among all included individuals and 5.7/100 PY among the proportion (11%) with continued IDU documented during follow-up.

Reinfection after DAA treatment

As HCV treatment for PWID becomes more feasible with IFN-free therapy, reinfection may become a more common event. The adverse events of IFN-based treatment have required close interaction with health care providers, offering opportunities for interventions aimed at achieving beneficial behavioural change [37,151]. For some, IFN itself might even have provided a “cathartic” effect, resulting in efforts to protect one’s SVR. One might therefore speculate that the potential for behavioural change will decrease in the emerging IFN-free era.

So far, no published studies have evaluated the risk of reinfection following DAA treatment, but some data has been presented as abstracts. Of 3004 patients who achieved SVR12 in the phase 3 studies of sofosbuvir [152], which notably excluded patients with recent illicit drug use or OST, 12 cases of recurrence of HCV RNA were identified after 3 months of follow-up. Based on results from deep sequencing of the NS5B segment, 7 of 12 cases represented reinfection while 5 of 12 cases represented late relapse. These findings suggest that among cases with HCV recurrence post-SVR12, most can be attributed to reinfection even in presumed low-risk populations.

Reinfection was also assessed in a recent study of elbasvir/grazoprevir in HCV patients receiving opioid agonist therapy [153]. Given that one-half of included individuals had detectable illicit drugs (excluding marijuana) in urine throughout the study, this population could be considered at high-risk of reinfection. SVR12 was achieved in 184 of 201 (91%) patients and virological failure could be attributed to relapse in 7 patients and

reinfection in 5 patients. The reinfection diagnosis was based on population-based sequencing of the NS3 and NS5A segments, supported by positive urinary drug screening in 4 of 5 individuals. Two of the cases with reinfection were subsequently HCV RNA negative, confirming that an important proportion of reinfections might clear spontaneously also after DAA treatment.

Incidence of HCV reinfection after SVR among MSM

Data on HCV reinfection among MSM are mainly limited to HIV-infected individuals. In addition, most studies have focused on reinfection following treatment of acute HCV infection [7,98,114,130,131], and few data are available on the incidence of reinfection after treatment of chronic HCV infection [7,125]. However, in a British study [7] among HIV/HCV co-infected MSM that included both acute infections and cases of unknown duration, data on reinfection was reported for 46 individuals with unknown date of HCV infection. Among those, 12 (26%) were reinfected after spontaneous or treatment-induced clearance. The overall reinfection rate was 7.8/100 PY, slightly lower than among individuals with acute HCV infection.

High rates of reinfection in HIV-positive MSM following successful treatment of acute HCV infection have been reported in several studies [7,98,114,130,131]. In a study from Amsterdam [98], 11 of 51 individuals who achieved SVR were reinfected after a median follow-up of 1.3 years. The incidence of reinfection was 15.2/100 PY and the cumulative incidence was 33% within 2 years. The reinfection diagnosis was supported by sequencing of the E2-HVR1 region, and behavioural data, available in 21 MSM, showed that non-injecting drug use was more frequent in reinfected individuals. In a study from London [7], 27 reinfections occurred among 114 individuals with SVR after treatment of acute infection, yielding a reinfection rate of 9.6/100 PY and a 2-year cumulative rate of 25%. In addition, there were six second reinfections occurring after successful treatment of the 13 first

Key point

Higher rates of reinfection might be expected in the DAA treatment era due to increased treatment access among people with on-going risk behaviour and less concerns for adverse effects of treatment.

Key point

The reported incidence of reinfection after SVR range from 2–6/100 PY in studies of PWID to 10–15/100 PY in studies of HIV-infected MSM.

reinfections. No behavioural data was reported in this study. The pooled reinfection rate for these two studies was 11.4/100 PY [131].

Two other studies estimated the frequency of reinfection after either spontaneous clearance or SVR during unreported periods of observation [114,130]. In a Dutch study [130], 12 of 31 (39%) HIV-infected MSM who obtained SVR after treatment of acute HCV infection were reinfected. In addition, four MSM were reinfected during treatment, before reaching SVR. Another study assessed reinfection after SVR in four sites in Germany from 2001 to 2013 [114]. Among 302 MSM with either spontaneous or treatment-induced clearance of acute HCV infection, 48 first reinfections (16%) were detected. Of those, 42 achieved SVR, one was reinfected again before reaching SVR and five spontaneously cleared their reinfection. After a median time of 13 months after HCV clearance, there were 11 second reinfections (personal communication, P. Ingiliz). All episodes occurred in MSM who did not report injecting drug use.

In a recent European multi-centre collaboration [132], the rates of reinfection were estimated among 606 HIV-positive MSM with confirmed SVR or spontaneous clearance. Over 3 years of follow-up, 149 patients (25%) were reinfected, with an overall incidence rate of 7.6/100 PY. A second, third and fourth reinfection were detected in 69, 13 and 2 individuals respectively, and the incidence of second reinfection was 19.9/100 PY. The incidence varied between cities, with highest rates observed in Paris (21.8/100 PY). Behavioural data was not reported in this study.

Risk behaviours have not been systematically assessed in these studies, and factors associated with reinfection have therefore not been clarified among MSM. It is, however, conceivable that they are similar to those reported for primary HCV infection. In particular, the introduction of “chemsex” has likely facilitated HCV transmission in certain sexual networks [89], driving a chain of primary infections and reinfections.

Key point

Individual- and population-level strategies to address and prevent reinfection include acknowledgement, education and counselling, harm reduction optimization, scaled-up treatment in high-risk groups, treatment of injecting networks, post-SVR screening and rapid treatment of reinfections.

Comparison of reinfection rates among PWID and MSM

Based on existing data from small and heterogeneous studies of IFN-based treatment to former and current PWID, the incidence of HCV reinfection following SVR is approximately 2/100 PY in people with a history of IDU, increasing to around 6/100 PY in people with on-going IDU. The cumulative overall risk of reinfection calculated from all studies of PWID or prisoners reporting data on PY is 2.1/100 PY (43 reinfections over 2082 PY; Table 2). This is a significant risk, but still lower than rates of primary HCV infection reported in PWID outside the treatment setting [115].

Data on reinfection after SVR among MSM are also limited, but the reported incidence rates are

considerably higher (10–15/100 PY) among HIV-infected MSM than among PWID, and may even exceed rates of primary HCV infection. The cumulative risk of reinfection calculated from studies of MSM reporting data on PY is 12.8/100 PY (38 reinfections over 296 PY; Table 2). These results, however, may not be generalizable to HIV-uninfected MSM. Moreover, epidemic outbreaks have been reported only in certain large cities, whereas acute HCV and reinfections continue to be uncommon among MSM in many areas with high prevalence of HIV/HCV co-infection [154].

There are some considerations to be made when interpreting the differences in reinfection rates between PWID and MSM. First, most studies among PWID were carried out in selected populations with chronic HCV infection, often including individuals without on-going risk behaviour at the time of treatment. Conversely, studies of MSM mainly included individuals with acute HCV infection who probably continued to be engaged in risk behaviours during and after treatment. Second, MSM often have multiple risk factors for reinfection, including drug use as a sexual enhancer. Furthermore, HIV infection is a biological risk factor for HCV transmission more prevalent among MSM than among PWID. Table 3 summarizes important epidemiological differences between PWID and MSM.

Addressing reinfection

High cumulative rates of reinfection are to be expected as we enter the IFN-free treatment era. This could negate individual long-term treatment benefits and challenge the potential to prevent HCV-related liver disease morbidity and mortality in high-risk populations. High rates of reinfection would also allow continued HCV transmission and might compromise population-level treatment-as-prevention benefits [12].

Efforts to address and prevent reinfection should therefore be undertaken when providing HCV care for people with on-going risk behaviour. Acknowledgement of the problem without stigma and discrimination is the crucial first step; reinfections will occur and simply confirms that the target population is being treated. However, individual-level prevention of reinfection faces the same challenges as prevention of primary infection, and there are no data evaluating the impact of such interventions on reinfection. Nevertheless, all patients should be offered information, education and counselling about the risk of reinfection associated with high-risk sexual practices and unsafe drug use [37,155]. Repeated safe sex counselling from health care providers and peers may be considered for HIV-infected MSM with high-risk behaviour [7,97–100]. Combined harm reduction interventions should be optimized for all active injectors and HCV care should preferably be integrated in multidisciplinary settings [37,156,157]. The potential role of a prophylactic

Table 3. Differences in hepatitis C epidemiology among people who inject drugs and men who have sex with men.

	PWID	MSM
HCV prevalence	High	Low*
Proportion of total HCV population	Large	Small
Access to HCV care	Poor	Good
Treatment of acute HCV infection	Rare	Common
Risk behaviours post-SVR	Variable	Prevalent
Transmission networks	Local	International
Reinfection rates	2-6/100 PY	10-15/100 PY

*Mainly limited to HIV-infected.

PWID, people who inject drugs; MSM, men who have sex with men; SVR, sustained virological response; PY, person-years.

HCV vaccine for high-risk groups remains to be seen, but results from an on-going vaccine trial among PWID are highly anticipated [117,158].

At the population-level, HCV treatment for high-risk groups could represent an opportunity for epidemic control [49,159]. Individuals at high-risk of reinfection are probably also the ones most likely to transmit the virus forward. Targeted antiviral treatment for high-risk transmitters may therefore have great prevention potential, as these individuals, even if only temporarily, are kept out of the viremic pool. Despite the lack of empirical data, this perspective is supported by current international treatment guidelines that recommend prioritized treatment for PWID and MSM regardless of fibrosis stage [160–162].

As HCV incidence will depend on the viremic prevalence in a given population, rapid treatment scale-up in high-risk populations could be necessary to reduce the impact of reinfection over time [163]. Conversely, a slow scale-up could create an increasing number of susceptible individuals without reduction of the viremic reservoir. Consequently, early detection and retreatment of reinfections may be required to counteract the negative effects of reinfection at both individual and population levels. Individuals with a high probability of continued high-risk behaviour after SVR should therefore undergo annual HCV RNA screening within a multidisciplinary treatment setting and quickly get access to retreatment if reinfection is detected.

PWID rarely contribute to international HCV transmission, but instead engage in small local networks of injection partners [164,165]. Injecting networks powerfully influence the transmission of HCV and could inform treatment-as-prevention strategies among PWID. In clinical practice, however, most often single persons within such networks are treated, resulting in a high reinfection risk. A feasible approach, both in settings of primary infection and reinfection, could therefore be to explore and treat whole networks using a “bring your friends”-strategy [166].

More data on reinfection are needed in a field rapidly moving forward. The incidence of reinfection following DAA treatment is unknown and should be assessed carefully in prospective clinical trials. Importantly, future research should evaluate the feasibility of potential prevention and retreatment strategies within controlled studies.

Conclusions

Current DAA treatment offers unique opportunities for reductions in HCV-related liver disease burden and epidemic control in high-risk populations of PWID and MSM. However, increasing rates of reinfection after successful treatment due to on-going risk behaviours should be anticipated and acknowledged without stigma. Constructive preventive strategies include education and counselling, harm reduction optimization, scaled-up treatment in high-risk groups including treatment of injecting networks, post-SVR screening, and rapid retreatment of reinfections.

Financial support

HM receives research grants from the Norwegian Extra Foundation for Health and Rehabilitation.

Conflict of interest

HM has received lecture fees from Abbvie, Gilead Sciences, Merck Sharp & Dohme, Roche and Medivir. VLR receives research grant funding (to the University of Pennsylvania) from AstraZeneca. JAP has received consulting and lecture fees and research support from Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare; consulting fees and research support from Pfizer; consulting and lecture fees from Gilead Sciences, Janssen-Cilag, and Merck Sharp & Dohme; research support and lecture fees from Roche; and research support from Schering-Plough. JM has received lectures fees from Roche, Gilead, Boehringer-Ingelheim, Abbvie and Bristol-Myers Squibb; and consulting fees from Boehringer-Ingelheim, Bristol-Myers-Squibb, Gilead Sciences, Abbvie and Merck Sharp & Dome. OD has received research support, consulting and lecture fees from Abbvie, Gilead Sciences and Merck Sharp & Dohme; and lecture fees from Medivir and Bristol-Myers Squibb.

Authors contributions

HM and OD drafted the following sections: Introduction, General considerations, Incidence of HCV

Key point

Future studies should assess the incidence of reinfection following DAA treatment and evaluate the feasibility of potential prevention and retreatment strategies.

reinfection after SVR among PWID, Comparison of reinfection rates among PWID and MSM, Addressing reinfection, and Conclusion. AW and NP drafted the section HCV epidemiology among PWID. VLR drafted the section HCV epidemiology among MSM. JAP and JM drafted the section Incidence of HCV reinfection after SVR among MSM. All authors critically reviewed the manuscript.

Acknowledgements

The authors would like to thank John H.-O. Petersson at the Norwegian Institute of Public Health for reviewing the section on HCV sequencing methods.

References

Author names in bold designate shared co-first authorship

- [1] Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011;378:571–583.
- [2] Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. *Nat Rev Gastroenterol Hepatol* 2013;10:553–562.
- [3] Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. *J Viral Hepat* 2014;21:5–33.
- [4] Prevost TC, Presanis AM, Taylor A, Goldberg DJ, Hutchinson SJ, De Angelis D. Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. *Addiction* 2015;110:1287–1300.
- [5] Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clin Infect Dis* 2013;57:S80–S89.
- [6] Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. *Clin Infect Dis* 2013;56:806–816.
- [7] Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. *Aids* 2013;27:2551–2557.
- [8] Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. *Liver Int* 2014;34:1198–1206.
- [9] Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. *J Viral Hepat* 2014;21:198–207.
- [10] Grebely J, Bruggmann P, Backmund M, Dore GJ. Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis* 2013;57:S29–S31.
- [11] Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? *J Hepatol* 2015;63:779–782.
- [12] Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. *Curr Opin Infect Dis* 2015;28:576–582.
- [13] United Nations office on drugs and crime. Word drug report 2013. Vienna: United Nations Office on Drugs and Crime; 2013. Available from: URL: <http://www.unodc.org/wdr/>.
- [14] Kaya CY, Tugai Y, Filar JA, Agrawal MR, Ali RL, Gowing LR, et al. Heroin users in Australia: population trends. *Drug Alcohol Rev* 2004;23:107–116.
- [15] Geraghty J. Drug policy, intravenous drug use, and heroin addiction in the UK. *Br J Nurs* 2011;20:884.
- [16] Lavanchy D. Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect* 2011;17:107–115.
- [17] Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. *Epidemiol Infect* 2014;142:270–286.
- [18] Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. *PLoS One* 2014;9:e103345.
- [19] Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatology* 2013;58:1215–1224.
- [20] Gerberding JL. Management of occupational exposures to blood-borne viruses. *N Engl J Med* 1995;332:444–451.
- [21] Yazdanpanah Y, De Carli G, Miguieres B, Lot F, Campins M, Colombo C, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. *Clin Infect Dis* 2005;41:1423–1430.
- [22] Tomkins SE, Elford J, Nichols T, Aston J, Cliffe SJ, Roy K, et al. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data. *J Viral Hepat* 2012;19:199–204.
- [23] Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. *Addiction* 2012;107:1057–1065.
- [24] Corson S, Greenhalgh D, Taylor A, Palmateer N, Goldberg DJ, Hutchinson S. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. *Drug Alcohol Depend* 2013;133:172–179.
- [25] Palmateer NE, Hutchinson SJ, Innes H, Schrier C, Wu O, Goldberg DJ, et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. *Int J Drug Policy* 2013;24:85–100.
- [26] Sharma M, Oppenheimer E, Saidel T, Loo V, Garg R. A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. *Aids* 2009;23:1405–1413.
- [27] Horyniak D, Dietze P, Degenhardt L, Higgs P, McLlwraith F, Alati R, et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. *Drug Alcohol Depend* 2013;132:541–546.
- [28] Burt RD, Thiede H. Reduction in Needle Sharing Among Seattle-Area Injection Drug Users Across 4 Surveys, 1994–2013. *Am J Public Health* 2016;106:301–307.
- [29] Public Health England. Shooting Up: Infections among people who inject drugs in the UK, 2014. An update, November 2015. London: Public Health England; 2015. Available from: URL: <https://www.gov.uk/government/publications/shooting-up-infections-among-people-who-inject-drugs-in-the-uk>.
- [30] **Lindenburg CE, Krol A, Smit C, Buster MC, Coutinho RA, Prins M.** Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. *Aids* 2006;20:1771–1775.
- [31] Fatseas M, Denis C, Serre F, Dubernet J, Daulouede JP, Auriacombe M. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. *AIDS Behav* 2012;16:2082–2090.
- [32] Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. *PLoS One* 2014;9:e104515.
- [33] Uuskula A, Raag M, Folch C, Prasad L, Karnite A, van Veen MG, et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West. *Aids* 2014;28:1657–1664.
- [34] Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. *J Viral Hepat* 2014;21:25–32.
- [35] Harm Reduction International. What is harm reduction? Available from: <http://www.hri.net/what-is-harm-reduction>.
- [36] Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. *Addiction* 2010;105:844–859.

- [37] MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. *Int J Drug Policy* 2014;25:34–52.
- [38] Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, Amsterdam C. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. *Addiction* 2007;102:1454–1462.
- [39] Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* 2011;106:1978–1988.
- [40] Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. *J Infect Dis* 2011;204:74–83.
- [41] Scottish Government. Hepatitis C action plan for Scotland. Phase II: May 2008–March 2011. Edinburgh: Scottish Government; 2008. Available from: URL: www.scotland.gov.uk/Resource/Doc/222750/0059978.pdf.
- [42] World Health Organization. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization; 2012.
- [43] European Centre for Disease Prevention and Control. Prevention and control of infectious diseases among people who inject drugs. Stockholm: European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction; 2011. Available from: URL: <http://www.wemcd-daeuropa.eu/publications/ecdc-emccda-guidance>.
- [44] National Institute for Health and Care Excellence. Needle and syringe programmes. NICE; 2014. Available from: URL: www.nice.org.uk/guidance/ph52.
- [45] Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. *Lancet* 2010;375:1014–1028.
- [46] Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, et al. Changes in blood-borne infection risk among injection drug users. *J Infect Dis* 2011;203:587–594.
- [47] Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. *Addiction* 2012;107:1984–1995.
- [48] Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. *Clin Infect Dis* 2013;57:S39–S45.
- [49] Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology* 2013;58:1598–1609.
- [50] Corona R, Prignano G, Mele A, Gentili G, Caprilli F, Franco E, et al. Heterosexual and homosexual transmission of hepatitis C virus: relation with hepatitis B virus and human immunodeficiency virus type 1. *Epidemiol Infect* 1991;107:667–672.
- [51] Buchbinder SP, Katz MH, Hessel NA, Liu J, O'Malley PM, Alter MJ. Hepatitis C virus infection in sexually active homosexual men. *J Infect* 1994;29:263–269.
- [52] Bodsworth NJ, Cunningham P, Kaldor J, Donovan B. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. *Genitourin Med* 1996;72:118–122.
- [53] van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *Aids* 2010;24:1799–1812.
- [54] Raymond HF, Chu P, Nieves-Rivera I, Louie B, McFarland W, Pandori M. Hepatitis C infection among men who have sex with men, San Francisco, 2011. *Sex Transm Dis* 2012;39:985–986.
- [55] Seaberg EC, Witt MD, Jacobson LP, Detels R, Rinaldo CR, Young S, et al. Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. *J Viral Hepat* 2014;21:696–705.
- [56] Tor J, Llibre JM, Carbonell M, Muga R, Ribera A, Soriano V, et al. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. *BMJ* 1990;301:1130–1133.
- [57] Ricchi E, Borderi M, Costigliola P, Miniero R, Sprovieri G, Chiodo F. Anti-hepatitis C virus antibodies amongst Italian homo-bisexual males. *Eur J Epidemiol* 1992;8:804–807.
- [58] Ndimbie OK, Kingsley LA, Nedjar S, Rinaldo CR. Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. *Genitourin Med* 1996;72:213–216.
- [59] Kouyos RD, Rauch A, Braun DL, Yang WL, Boni J, Yerly S, et al. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. *J Infect Dis* 2014;210:1555–1561.
- [60] Alary M, Joly JR, Vincelette J, Lavoie R, Turmel B, Remis RS. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. *Am J Public Health* 2005;95:502–505.
- [61] Myers T, Allman D, Xu K, Remis RS, Aguinaldo J, Burchell A, et al. The prevalence and correlates of hepatitis C virus (HCV) infection and HCV-HIV co-infection in a community sample of gay and bisexual men. *Int J Infect Dis* 2009;13:730–739.
- [62] Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. *Aids* 2009;23:F1–F7.
- [63] Jin F, Prestage GP, Matthews G, Zablotska I, Rawstorne P, Kippax SC, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. *Sex Transm Infect* 2010;86:25–28.
- [64] Browne R, Asboe D, Gilleece Y, Atkins M, Mandalia S, Gazzard B, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? *Sex Transm Infect* 2004;80:326–327.
- [65] Gambotti L, Batisse D, Colin-de-Verdiere N, Delarouge-Astagneau E, Desclos JC, Dominguez S, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001–2004. *Euro Surveill* 2005;10:115–117.
- [66] Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. *J Acquir Immune Defic Syndr* 2005;40:41–46.
- [67] Gotz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men—results from contact tracing and public health implications. *Aids* 2005;19:969–974.
- [68] Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. *Clin Infect Dis* 2005;41:395–402.
- [69] Ghosn J, Deveau C, Goujard C, Garrigue I, Saichi N, Galimand J, et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. *Sex Transm Infect* 2006;82:458–460.
- [70] Turner JM, Rider AT, Imrie J, Copas AJ, Edwards SG, Dodds JP, et al. Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men. *Sex Transm Infect* 2006;82:298–300.
- [71] van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. *J Infect Dis* 2007;196:230–238.
- [72] Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002–2006: is this an outbreak? *Sex Transm Infect* 2008;84:111–115.
- [73] Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. *J Infect Dis* 2008;197:1213–1214. [Author reply 1214–1215].
- [74] Ruan Y, Luo F, Jia Y, Li X, Li Q, Liang H, et al. Risk factors for syphilis and prevalence of HIV, hepatitis B and C among men who have sex with men in Beijing, China: implications for HIV prevention. *AIDS Behav* 2009;13:663–670.
- [75] Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. *Clin Infect Dis* 2011;52:812–818.
- [76] van der Helm JJ, Prins M, del Amo J, Bucher HC, Chene G, Dorrucci M, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. *Aids* 2011;25:1083–1091.
- [77] Sun HY, Chang SY, Yang ZY, Lu CL, Wu H, Yeh CC, et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. *J Clin Microbiol* 2012;50:781–787.
- [78] Wandeler G, Gsponer T, Bregenzner A, Gunthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. *Clin Infect Dis* 2012;55:1408–1416.

- [79] Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011. *Clin Infect Dis* 2013;57:77–84.
- [80] Nishijima T, Shimbo T, Komatsu H, Hamada Y, Gatanaga H, Oka S. Incidence and risk factors for incident Hepatitis C infection among men who have sex with men with HIV-1 infection in a large Urban HIV clinic in Tokyo. *J Acquir Immune Defic Syndr* 2014;65:213–217.
- [81] Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. *Sex Transm Infect* 2012;88:558–564.
- [82] van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology* 2009;136:1609–1617.
- [83] Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? *Curr Opin Infect Dis* 2013;26:66–72.
- [84] Centers for disease, control prevention, sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005–2010. *MMWR Morb Mortal Wkly Rep* 2011;2011:945–950.
- [85] Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *Aids* 2007;21:983–991.
- [86] Hatfield LA, Horvath KJ, Jacoby SM, Simon Rosser BR. Comparison of substance use and risky sexual behavior among a diverse sample of urban, HIV-positive men who have sex with men. *J Addict Dis* 2009;28:208–218.
- [87] Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric I, et al. Trouble with bleeding: risk factors for hepatitis C among HIV-positive gay men from Germany—a case-control study. *PLoS One* 2011;6:e17781.
- [88] Larsen C, Chaix ML, Le Strat Y, Velter A, Gervais A, Auferin I, et al. Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study. *PLoS One* 2011;6:e29322.
- [89] Page EE, Nelson M. Hepatitis C and sex. *Clin Med (Lond)* 2016;16:189–192.
- [90] Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. *Gastroenterology* 2005;128:313–327.
- [91] Leruez-Ville M, Kunstmann JM, De Almeida M, Rouzioux C, Chaix ML. Detection of hepatitis C virus in the semen of infected men. *Lancet* 2000;356:42–43.
- [92] Pasquier C, Bujan L, Daudin M, Righi L, Berges L, Thauvin L, et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. *J Med Virol* 2003;69:344–349.
- [93] Briat A, Duloust E, Galimand J, Fontaine H, Chaix ML, Letur-Konirsch H, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. *Aids* 2005;19:1827–1835.
- [94] Apers L, Vanden Bergh W, De Wit S, Kabeya K, Callens S, Buyze J, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. *J Acquir Immune Defic Syndr* 2015;68:585–593.
- [95] Wong J, Moore D, Kanters S, Buxton J, Robert W, Gustafson R, et al. Seroprevalence of hepatitis C and correlates of seropositivity among men who have sex with men in Vancouver, Canada: a cross-sectional survey. *Sex Transm Infect* 2015;91:430–433.
- [96] **Martin NK, Thornton A**, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. *Clin Infect Dis* 2016;62:1072–1080.
- [97] Owen G. An 'elephant in the room'? Stigma and hepatitis C transmission among HIV-positive 'serosorting' gay men. *Cult Health Sex* 2008;10:601–610.
- [98] Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. *Aids* 2011;25:F21–F27.
- [99] Lea T, Mao L, Bath N, Prestage G, Zablotska I, de Wit J, et al. Injecting drug use among gay and bisexual men in Sydney: prevalence and associations with sexual risk practices and HIV and hepatitis C infection. *AIDS Behav* 2013;17:1344–1351.
- [100] Amirkhanian YA, Kelly JA, Takacs J, McAuliffe TL, Kuznetsova AV, Toth TP, et al. Effects of a social network HIV/STD prevention intervention for MSM in Russia and Hungary: a randomized controlled trial. *Aids* 2015;29:583–593.
- [101] Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees challenged following clearance of primary infection. *Hepatology* 2001;33:1479–1487.
- [102] Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, Andrus L, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. *J Infect Dis* 2005;192:1701–1709.
- [103] Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. *Lancet* 2002;359:1478–1483.
- [104] den Hollander JG, Rijnders BJ, van Doornum GJ, van der Ende ME. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. *Aids* 2005;19:639–640.
- [105] Grebely J, Conway B, Raffa JD, Lai C, Kraiden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. *Hepatology* 2006;44:1139–1145.
- [106] Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. *J Viral Hepat* 2007;14:413–418.
- [107] Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. *Hepatology* 2008;48:1746–1752.
- [108] Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. *J Infect Dis* 2009;200:1216–1226.
- [109] Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. *Gastroenterology* 2010;138:315–324.
- [110] Jones R, Brown D, Nelson M, Low E, Bhagani S, Atkins M, et al. Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence? *J Acquir Immune Defic Syndr* 2010;53:547–550.
- [111] Pham ST, Bull RA, Bennett JM, Rawlinson WD, Dore GJ, Lloyd AR, et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. *Hepatology* 2010;52:1564–1572.
- [112] Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. *PLoS One* 2013;8:e80216.
- [113] Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, et al. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC3 Study. *J Infect Dis* 2015;212:1407–1419.
- [114] Ingiliz P, Krznaric I, Stellbrink HJ, Knecht G, Lutz T, Noah C, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. *HIV Med* 2014;15:355–361.
- [115] Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. *Lancet Infect Dis* 2012;12:408–414.
- [116] Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. *J Hepatol* 2011;54:1273–1285.
- [117] Freeman ZT, Cox AL. Lessons from nature: understanding immunity to HCV to guide vaccine design. *PLoS Pathog* 2016;12:e1005632.
- [118] Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. *Eur Addict Res* 2002;8:45–49.
- [119] Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. *Clin Infect Dis* 2004;39:1540–1543.
- [120] Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. *Drug Alcohol Depend* 2008;93:148–154.
- [121] Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. *J Gastroenterol Hepatol* 2010;25:1281–1284.
- [122] **Grady BP, Vanhommerig JW**, Schinkel J, Weegink CJ, Bruisten SM, Lindenburg CE, et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. *Eur J Gastroenterol Hepatol* 2012;24:1302–1307.
- [123] **Grebely J, Pham ST**, Matthews GV, Petoumenos K, Bull RA, Yeung B, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. *Hepatology* 2012;55:1058–1069.
- [124] Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of

- hepatitis C virus infection in people actively using drugs: a randomized controlled trial. *Clin Infect Dis* 2013;57:S90–S96.
- [125] Pineda JA, Nunez-Torres R, Tellez F, Mancebo M, Garcia F, Merchante N, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. *J Infect* 2015;71:571–577.
 - [126] Midgard H, Bjoro B, Maeland A, Konopski Z, Kileng H, Damas JK, et al. Hepatitis C reinfection after sustained virological response. *J Hepatol* 2016;64:1020–1026.
 - [127] Weir A, McLeod A, Innes H, Valerio H, Aspinall EJ, Goldberg DJ, et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. *Drug Alcohol Depend* 2016;165:53–60.
 - [128] Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. *J Gastroenterol Hepatol* 2010;25:1276–1280.
 - [129] Marco A, Esteban JI, Sole C, da Silva A, Ortiz J, Roget M, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. *J Hepatol* 2013;59:45–51.
 - [130] Vanhommerig JW, Thomas XV, van der Meer JT, Geskus RB, Bruisten SM, Molenkamp R, et al. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. *Clin Infect Dis* 2014;59:1678–1685.
 - [131] Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. *Aids* 2015;29:2335–2345.
 - [132] Martin TC, Ingiliz P, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, et al. HCV reinfection incidence and outcomes among HIV-infected MSM in Western Europe. *EASL International Liver Congress 2016 Barcelona*, April 13–17, 2016 Abstract P5006 2016.
 - [133] Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. *J Infect Dis* 2012;205:1342–1350.
 - [134] Sacks-Davis R, McBryde E, Grebely J, Hellard M, Vickerman P. Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. *J R Soc Interface* 2015;12:20141197.
 - [135] Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. *Clin Infect Dis* 2013;57:S105–S110.
 - [136] Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. *Nat Rev Gastroenterol Hepatol* 2015;12:218–230.
 - [137] Jacka B, Lamoury F, Simmonds P, Dore GJ, Grebely J, Applegate T. Sequencing of the hepatitis C virus: a systematic review. *PLoS One* 2013;8:e67073.
 - [138] Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. *CID*, 2005.
 - [139] Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. *Hepatitis Interventional Therapy Group. Ann Intern Med* 1996;124:868–876.
 - [140] Aitken C, McCaw R, Jardine D, Bowden S, Higgs P, Nguyen O, et al. Change in hepatitis C virus genotype in injecting drug users. *J Med Virol* 2004;74:543–545.
 - [141] Bowden S, McCaw R, White PA, Crofts N, Aitken CK. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. *J Viral Hepat* 2005;12:322–324.
 - [142] Micallessi MI, Gerard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004–2005. *J Med Virol* 2008;80:640–645.
 - [143] Sereno S, Perinelli P, Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users—relation to period of injection started. *J Clin Virol* 2009;45:354–357.
 - [144] Herring BL, Page-Shafer K, Tobler LH, Delwart EL. Frequent hepatitis C virus superinfection in injection drug users. *J Infect Dis* 2004;190:1396–1403.
 - [145] van de Laar TJ, Molenkamp R, van den Berg C, Schinkel J, Beld MG, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. *J Hepatol* 2009;51:667–674.
 - [146] Abdelrahman T, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. *Hepatology* 2015;61:88–97.
 - [147] Schroter M, Feucht HH, Zollner B, Schafer P, Laufs R. Multiple infections with different HCV genotypes: prevalence and clinical impact. *J Clin Virol* 2003;27:200–204.
 - [148] Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? *J Infect Dis* 2014;209:38–45.
 - [149] Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. *Clin Infect Dis* 2011;52:889–900.
 - [150] Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. *Clin Infect Dis* 2016;62:683–694.
 - [151] Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. *Int J Drug Policy* 2015;26:976–983.
 - [152] Sarrazin C, Isakov V, Svarovskaia E, Martin R, Chodavarapu K, Hedskog C, et al. HCV reinfection in phase 3 studies of sofosbuvir. *J Hepatol* 2015;62:S222–S223.
 - [153] Dore GJ, Altice FL, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir and grazoprevir in persons with HCV receiving opioid agonist therapy (C-EDGE CO-STAR). 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13–17 2015, 2015.
 - [154] Quintana R, Neukam K, Viciano P, Ojeda-Burgos G, Delgado-Fernández M, Ríos MJ. No evidence of acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain. National Conference of the Group for the Study of Viral Hepatitis (GEHEP) of SEIMC 24–26 September 2015, Vigo, Spain Abstract OR-10 Available at *AIDS Rev (Suppl)* 2015;17: 9 2015.
 - [155] Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. *Int J Drug Policy* 2012;23:176–184.
 - [156] Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. *Clin Infect Dis* 2013;57:S32–S38.
 - [157] Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clin Infect Dis* 2013;57:S56–S61.
 - [158] Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. *Clin Infect Dis* 2013;57:S46–S50.
 - [159] de Vos AS, Prins M, Kretzschmar ME. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? *Addiction* 2015;110:975–983.
 - [160] European Association for the Study of the Liver. *EASL recommendations on treatment of hepatitis C* 2015. *J Hepatol* 2015;63:199–236.
 - [161] AASLD-IDS Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. URL:<http://www.hcvguidelines.org>. Accessed: 2016-06-20. (Archived by WebCite® at <http://www.webcitation.org/6iPAiC0wA>).
 - [162] Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy* 2015;26:1028–1038.
 - [163] Razavi H, Grebely J, Wilson DJ, , Estes C, Dore GJ. Modeling the impact of hepatitis C virus (HCV) treatment as prevention among people who inject drugs (PWIDs) in Australia. 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015), Sydney, Australia, Oct 7–9, 2015 2015.
 - [164] Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. *Hepatology* 2014;60:1861–1870.
 - [165] Morris MD, Evans J, Montgomery M, Yu M, Briceno A, Page K, et al. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. *PLoS One* 2014;9:e109282.
 - [166] Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, et al. Hepatitis C transmission and treatment as prevention – The role of the injecting network. *Int J Drug Policy* 2015;26:958–962.